Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center, Hackensack University Medical Center, shared JCO Precision Oncology’s post on LinkedIn, adding:
“HER2 NSCLC getting crowded with zongertinib, T-DXD, TDM1, sevabertinib.
Take- ~3% of NSCLC. 2L treatments are suboptimal. OS of ~13.5 months can be improved.”
Quoting JCO Precision Oncology’s post:
“New content alert
Patients with advanced or metastatic NSCLC with HER2 mutations were diagnosed between January 1, 2015, and June 30, 2022. ”
Title: Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2-Mutant Non–Small Cell Lung Cancer
Authors: Christine M. Lovly, Christina Baik, Misako Nagasaka, Tejas Patil, Sonia S. Maruti, Stephen Stanhope, Neslihan A. Kaya, Stephan Herbertz, Beth Nordstrom, Kathryn Evans, Xiuning Le
Read the Full Article.
You can also read:
PD-L1 High Advanced NSCLC: Is Immunotherapy Alone Always Enough?
